title: Preventive Strategies for Vascular Calcification in Patients with Chronic Kidney Disease.
abstract: Vascular calcification is significant because of the close association between the degree of vascular calcification and cardiovascular mortality in chronic kidney disease (CKD) patients.
  
  
  
  There are 2 types of vascular calcification in CKD patients. One is endothelial vascular calcification, a common type of vascular calcification. Another is medial vascular calcification, a specific type that is common in CKD patients. The former is mainly associated with atherosclerosis due to hyperlipidemia, especially hypercholesterolemia. The latter CKD-specific type is called Moenckeberg's arteriosclerosis. A known risk factor for this type of vascular calcification is hyperphosphatemia. In this review article, we mainly discuss a preventive strategy for Moenckeberg type vascular calcification in CKD, primarily involving the treatment of hyperphosphatemia. Several possible modalities are considered. However, at present, dietary restriction of phosphate is not recommended so as to avoid malnutrition in CKD patients. The first consideration is the enhancement of phosphate removal by renal replacement therapy in dialysis patients. Various phosphate binder therapies can be beneficial and effective. Surgical and pharmacological parathyroidectomies are also useful for treating secondary hyperparathyroidism. Good quality bone provides a good pool of calcium and phosphate. Thus, bone protection is another option for preventing vascular calcification. Several therapeutic agents have been developed to manage osteoporosis. These trial agents may be reasonably effective in impeding the progression of vascular calcification in CKD patients. Key Messages: We should make full use of several modalities so as to completely prevent vascular calcification.
authors.forename: Takashi
authors.initials: T
authors.lastname: Shigematsu
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Sonou
authors.forename: Masaki
authors.initials: M
authors.lastname: Ohya
authors.forename: Keitaro
authors.initials: K
authors.lastname: Yokoyama
authors.forename: Hiraku
authors.initials: H
authors.lastname: Yoshida
authors.forename: Takashi
authors.initials: T
authors.lastname: Yokoo
authors.forename: Kouji
authors.initials: K
authors.lastname: Okuda
authors.forename: Asuka R
authors.initials: AR
authors.lastname: Masumoto
authors.forename: Yuko
authors.initials: Y
authors.lastname: Iwashita
authors.forename: Keiko
authors.initials: K
authors.lastname: Iseki
authors.forename: Satoko
authors.initials: S
authors.lastname: Kunimoto
authors.forename: Yukiko
authors.initials: Y
authors.lastname: Yamano
mesh_terms: D050197:Atherosclerosis; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy / Q000601:surgery; D054559:Hyperphosphatemia / Q000188:drug therapy / Q000628:therapy; D006435:Renal Dialysis; D051436:Renal Insufficiency, Chronic / Q000150:complications*; D061205:Vascular Calcification / Q000209:etiology / Q000517:prevention & control*